

Topical Collection

Advances in Ebolavirus, Marburgvirus, and Cuevavirus Research

Message from the Collection Editor

Filoviruses (cuevaviruses, ebolaviruses, and marburgviruses) are exotic high-consequence human and animal pathogens that must be handled in maximum (biosafety level 4) containment. This topic collection aims at providing an opportunity for filovirologists and other experts to publish not only general articles or reviews on any filovirus research topic, but also to distribute announcements of committee discussions or decisions, meeting reports, facility or method descriptions, and personal viewpoints or hypotheses. The goal of this open access topic collection is to further communication among interested scientists with particular emphasis on providing citable information on thoughts or ideas generally “known in the community” that are yet unpublished. Sincerely,
Jens H. Kuhn

Collection Editor

Dr. Jens H. Kuhn

NIH/NIAID Integrated Research Facility at Fort Detrick (IRF-Frederick),
B-8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/2310

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).